TWEAK/Fn14 axis: A promising target for the treatment of cardiovascular diseases

Frontiers in Immunology

Volumn 5, Issue JAN, 2014, Pages

  Blanco Colio, Luis M ^a  

^a UAM)   (Spain)

Author keywords

Atherosclerosis; Biomarker; Stroke; TNF superfamily; TWEAK

Indexed keywords

BIOLOGICAL MARKER; CD40 LIGAND; CYTOKINE RECEPTOR; FIBROBLAST GROWTH FACTORINDUCIBLE MOLECULE 14; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOTOXIN BETA RECEPTOR; METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; STRESS ACTIVATED PROTEIN KINASE 1; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR; TWEAK; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BONE MARROW TRANSPLANTATION; CARDIOVASCULAR DISEASE; CAROTID ARTERY OBSTRUCTION; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; HUMAN; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; PROGNOSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 84895558806     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00003     Document Type: Article

References (127)

1. Bodmer JL, Schneider P, Tschopp J. The molecular architecture of the TNF superfamily. Trends Biochem Sci (2002) 27:19-26. doi:10.1016/S0968-0004(01)01995-8.
2. Napetschnig J, Wu H. Molecular basis of NF-κB signaling. Annu Rev Biophys (2013) 42:443-68. doi:10.1146/annurev-biophys-083012-130338.
3. Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, Hession C, et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem (1997) 272:32401-10. doi:10.1074/jbc.272.51.32401.
4. Wiley SR, Cassiano L, Lofton T, Davis-Smith T, Winkles JA, Lindner V, et al. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity (2001) 15:837-46. doi:10.1016/S1074-7613(01)00232-1.
5. Feng SL, Guo Y, Factor VM, Thorgeirsson SS, Bell DW, Testa JR, et al. The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am J Pathol (2000) 156:1253-61. doi:10.1016/S0002-9440(10)64996-6.
6. Brown SA, Hanscom HN, Vu H, Brew SA, Winkles JA. TWEAK binding to the Fn14 cysteine-rich domain depends on charged residues located in both the A1 and D2 modules. Biochem J (2006) 397:297-304. doi:10.1042/BJ20051362.
7. Brown SA, Richards CM, Hanscom HN, Feng SL, Winkles JA. The Fn14 cytoplasmic tail binds tumour-necrosis-factor-receptor-associated factors 1, 2, 3 and 5 and mediates nuclear factor-kappaB activation. Biochem J (2003) 371:395-403. doi:10.1042/BJ20021730.
8. Bover LC, Cardó-Vila M, Kuniyasu A, Sun J, Rangel R, Takeya M, et al. A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications. J Immunol (2007) 178:8183-94.
9. Moreno JA, Muñoz-García B, Martín-Ventura JL, Madrigal-Matute J, Orbe J, Páramo JA, et al. The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. Atherosclerosis (2009) 207:103-10. doi:10.1016/j.atherosclerosis.2009.04.033.
10. Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK, et al. Identification of the haemoglobin scavenger receptor. Nature (2001) 409:198-201. doi:10.1038/35051594.
11. Fick A, Lang I, Schäfer V, Seher A, Trebing J, Weisenberger D, et al. Studies of binding of tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) to fibroblast growth factor 14 (Fn14). J Biol Chem (2012) 287:484-95. doi:10.1074/jbc.M111.287656.
12. Polek TC, Talpaz M, Darnay BG, Spivak-Kroizman T. TWEAK mediates signal transduction and differentiation of RAW264.7 cells in the absence of Fn14/TweakR. Evidence for a second TWEAK receptor. J Biol Chem (2003) 278:32317-23. doi:10.1074/jbc.M302518200.
13. Burkly LC, Michaelson JS, Hahm K, Jakubowski A, Zheng TS. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine (2007) 40:1-16. doi:10.1016/j.cyto.2007.09.007.
14. Tirnitz-Parker JE, Viebahn CS, Jakubowski A, Klopcic BR, Olynyk JK, Yeoh GC, et al. Tumor necrosis factor like weak inducer of apoptosis is a mitogen for liver progenitor cells. Hepatology (2010) 52:291-302. doi:10.1002/hep.23663.
15. Mustonen E, Sakkinen H, Tokola H, Isopoussu E, Aro J, Leskinen H, et al. Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) and its receptor Fn14 during cardiac remodelling in rats. Acta Physiol (Oxf) (2010) 199:11-22. doi:10.1111/j.1748-1716.2010.02080.x.
16. Dohi T, Borodovsky A, Wu P, Shearstone JR, Kawashima R, Runkel L, et al. TWEAK/Fn14 pathway: a nonredundant role in intestinal damage in mice through a TWEAK/intestinal epithelial cell axis. Gastroenterology (2009) 136:912-23. doi:10.1053/j.gastro.2008.11.017.
17. Mittal A, Bhatnagar S, Kumar A, Lach-Trifilieff E, Wauters S, Li H, et al. The TWEAK-Fn14 system is a critical regulator of denervation-induced skeletal muscle atrophy in mice. J Cell Biol (2010) 188:833-49. doi:10.1083/jcb.200909117.
18. Muñoz-García B, Martín-Ventura JL, Martínez E, Sánchez S, Hernández G, Ortega L, et al. Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: modulation by atorvastatin. Stroke (2006) 37:2044-53. doi:10.1161/01.STR.0000230648.00027.00.
19. Desplat-Jégo S, Creidy R, Varriale S, Allaire N, Luo Y, Bernard D, et al. Anti-TWEAK monoclonal antibodies reduce immune cell infiltration in the central nervous system and severity of experimental autoimmune encephalomyelitis. Clin Immunol (2005) 117:15-23. doi:10.1016/j.clim.2005.06.005.
20. Justo P, Sanz AB, Sanchez-Nino MD, Winkles JA, Lorz C, Egido J, et al. Cytokine cooperation in renal tubular cell injury: the role of TWEAK. Kidney Int (2006) 70:1750-8. doi:10.1038/sj.ki.5001866.
21. Jain M, Jakubowski A, Cui L, Shi J, Su L, Bauer M, et al. A novel role for tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in the development of cardiac dysfunction and failure. Circulation (2009) 119:2058-68. doi:10.1161/CIRCULATIONAHA.108.837286.
22. Brown SA, Ghosh A, Winkles JA. Full-length, membrane-anchored TWEAK can function as a juxtacrine signaling molecule and activate the NF-kappaB pathway. J Biol Chem (2010) 285:17432-41. doi:10.1074/jbc.M110.131979.
23. Donohue PJ, Richards CM, Brown SA, Hanscom HN, Buschman J, Thangada S, et al. TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity. Arterioscler Thromb Vasc Biol (2003) 23:594-600. doi:10.1161/01.ATV.0000062883.93715.37.
24. Maecker H, Varfolomeev E, Kischkel F, Lawrence D, Leblanc H, Lee W, et al. TWEAK attenuates the transition from innate to adaptive immunity. Cell (2005) 123:931-44. doi:10.1016/j.cell.2005.09.022.
25. Chorianopoulos E, Heger T, Lutz M, Frank D, Bea F, Katus HA, et al. FGF inducible 14-kDa protein (Fn14) is regulated via the RhoA/ROCK kinase pathway in cardiomyocytes and mediates nuclear factor-kappaB activation by TWEAK. Basic Res Cardiol (2010) 105:301-13. doi:10.1007/s00395-009-0046-y.
26. Nakayama M, Kayagaki N, Yamaguchi N, Okumura K, Yagita H. Involvement of TWEAK in interferon γ-stimulated monocyte cytotoxicity. J Exp Med (2000) 192:1373-80. doi:10.1084/jem.192.9.1373.
27. Saitoh T, Nakayama M, Nakano H, Yagita H, Yamamoto N, Yamaoka S. TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation. J Biol Chem (2003) 278:36005-12. doi:10.1074/jbc.M304266200.
28. Muñoz-García B, Moreno JA, López-Franco O, Sanz AB, Martín-Ventura JL, Blanco J, et al. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) enhances vascular and renal damage induced by hyperlipidemic diet in ApoE-knockout mice. Arterioscler Thromb Vasc Biol (2009) 29:2061-8. doi:10.1161/ATVBAHA.109.194852.
29. Moreno JA, Sastre C, Madrigal-Matute J, Muñoz-García B, Ortega L, Burkly LC, et al. HMGB1 expression and secretion are increased via TWEAK-Fn14 interaction in atherosclerotic plaques and cultured monocytes. Arterioscler Thromb Vasc Biol (2013) 33:612-20. doi:10.1161/ATVBAHA.112.300874.
30. Sanz AB, Sanchez-Niño MD, Izquierdo MC, Jakubowski A, Justo P, Blanco-Colio LM, et al. TWEAK activates the non-canonical NFkappaB pathway in murine renal tubular cells: modulation of CCL21. PLoS One (2010) 5:e8955. doi:10.1371/journal.pone.0008955.
31. Damås JK, Smith C, Øie E, Fevang B, Halvorsen B, Waehre T, et al. Enhanced expression of the homeostatic chemokines CCL19 and CCL21 in clinical and experimental atherosclerosis: possible pathogenic role in plaque destabilization. Arterioscler Thromb Vasc Biol (2007) 27:614-20. doi:10.1161/01.ATV.0000255581.38523.7c.
32. Burkly LC, Michaelson JS, Zheng TS. TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses. Immunol Rev (2011) 244:99-114. doi:10.1111/j.1600-065X.2011.01054.x.
33. Hosokawa Y, Hosokawa I, Ozaki K, Nakae H, Matsuo T. Proinflammatory effects of tumour necrosis factor-like weak inducer of apoptosis (TWEAK) on human gingival fibroblasts. Clin Exp Immunol (2006) 146:540-9. doi:10.1111/j.1365-2249.2006.03233.x.
34. Li H, Mittal A, Paul PK, Kumar M, Srivastava DS, Tyagi SC, et al. Tumor necrosis factor-related weak inducer of apoptosis augments matrix metalloproteinase 9 (MMP-9) production in skeletal muscle through the activation of nuclear factor-kappaB-inducing kinase and p38 mitogen-activated protein kinase: a potential role of MMP-9 in myopathy. J Biol Chem (2009) 284:4439-50. doi:10.1074/jbc.M805546200.
35. Srivastava AK, Qin X, Wedhas N, Arnush M, Linkhart TA, Chadwick RB, et al. Tumor necrosis factor-alpha augments matrix metalloproteinase-9 production in skeletal muscle cells through the activation of transforming growth factor-beta-activated kinase 1 (TAK1)-dependent signaling pathway. J Biol Chem (2007) 282:35113-24. doi:10.1074/jbc.M705329200.
36. Kumar M, Makonchuk DY, Li H, Mittal A, Kumar A. TNF-like weak inducer of apoptosis (TWEAK) activates proinflammatory signaling pathways and gene expression through the activation of TGF-beta-activated kinase 1. J Immunol (2009) 182:2439-48. doi:10.4049/jimmunol.0803357.
37. Dogra C, Hall SL, Wedhas N, Linkhart TA, Kumar A. Fibroblast growth factor inducible 14 (Fn14) is required for the expression of myogenic regulatory factors and differentiation of myoblasts into myotubes. Evidence for TWEAK-independent functions of Fn14 during myogenesis. J Biol Chem (2007) 282:15000-10. doi:10.1074/jbc.M608668200.
38. Jakubowski A, Browning B, Lukashev M, Sizing I, Thompson JS, Benjamin CD, et al. Dual role for TWEAK in angiogenic regulation. J Cell Sci (2002) 115:267-74.
39. Lynch CN, Wang YC, Lund JK, Chen YW, Leal JA, Wiley SR. TWEAK induces angiogenesis and proliferation of endothelial cells. J Biol Chem (1999) 274:8455-9. doi:10.1074/jbc.274.13.8455.
40. Meighan-Mantha RL, Hsu DK, Guo Y, Brown SA, Feng SL, Peifley KA, et al. The mitogen-inducible Fn14 gene encodes a type I transmembrane protein that modulates fibroblast adhesion and migration. J Biol Chem (1999) 274:33166-76. doi:10.1074/jbc.274.46.33166.
41. Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov (2008) 7:411-25. doi:10.1038/nrd2488.
42. Glass CK, Witzum JL. Atherosclerosis: the road ahead. Cell (2001) 104:503-16. doi:10.1016/S0092-8674(01)00238-0.
43. Moreno JA, Dejouvencel T, Labreuche J, Smadja DM, Dussiot M, Martin-Ventura JL, et al. Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio. Arterioscler Thromb Vasc Biol (2010) 30:1253-62. doi:10.1161/ATVBAHA.110.203364.
44. Martín-Ventura JL, Lindholt JS, Moreno JA, Vega de Céniga M, Meilhac O, Michel JB, et al. Soluble TWEAK plasma levels predict expansion of human abdominal aortic aneurysms. Atherosclerosis (2011) 214:486-9. doi:10.1016/j.atherosclerosis.2010.11.009.
45. Harada N, Nakayama M, Nakano H, Fukuchi Y, Yagita H, Okumura K. Pro-inflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells. Biochem Biophys Res Commun (2002) 299:488-93. doi:10.1016/S0006-291X(02)02670-0.
46. Han S, Yoon K, Lee K, Kim K, Jang H, Lee NK, et al. TNF-related weak inducer of apoptosis receptor, a TNF receptor superfamily member, activates NF-kappa B through TNF receptor-associated factors. Biochem Biophys Res Commun (2003) 305:789-96. doi:10.1016/S0006-291X(03)00852-0.
47. Pamukcu B, Lip GYH, Shantsila E. The nuclear factor-kappa B pathway in atherosclerosis: a potential therapeutic target for atherothrombotic vascular disease. Thromb Res (2011) 128:117-23. doi:10.1016/j.thromres.2011.03.025.
48. Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, et al. Activated transcription factor nuclear factor kappa B is present in the atherosclerotic lesion. J Clin Invest (1996) 97:1715-22. doi:10.1172/JCI118598.
49. Bourcier T, Sukhova G, Libby P. The nuclear factor kappa-B signaling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis. J Biol Chem (1997) 272:15817-24. doi:10.1074/jbc.272.25.15817.
50. Martin-Ventura JL, Blanco-Colio LM, Munoz-Garcia B, Gomez-Hernandez A, Arribas A, Ortega L, et al. NF-kappaB activation and Fas ligand overexpression in blood and plaques of patients with carotid atherosclerosis: potential implication in plaque instability. Stroke (2004) 35:458-63. doi:10.1161/01.STR.0000114876.51656.7A.
51. Droga C, Changotra H, Mohan S, Kumar A. Tumor necrosis factor-like inducer of apoptosis inhibits skeletal myogenesis through sustained activation of nuclear factor kappa B and degradation of MyoD protein. J Biol Chem (2006) 281:10327-33. doi:10.1074/jbc.M511131200.
52. Ho DH, Vu H, Brown SA, Donohue PJ, Hanscom HN, Winkles JA. Soluble tumor necrosis factor-like weak inducer of apoptosis overexpression in HEK293 cells promotes tumor growth and angiogenesis in athymic nude mice. Cancer Res (2004) 64:8968-72. doi:10.1158/0008-5472.CAN-04-1879.
53. Sastre C, Fernández-Laso V, Madrigal-Matute J, Muñoz-García B, Moreno JA, Pastor-Vargas C, et al. Genetic deletion or TWEAK blocking antibody administration reduce atherosclerosis and enhance plaque stability in mice. J Cell Mol Med (2013). doi:10.1111/jcmm.12221.
54. Andersson U, Erlandsson-Harris H, Yang H, Tracey KJ. HMGB1 as a DNA-binding cytokine. J Leukoc Biol (2002) 72:1084-91.
55. Schapira K, Burkly LC, Zheng TS, Wu P, Groeneweg M, Rousch M, et al. Fn14-Fc fusion protein regulates atherosclerosis in ApoE-/- mice and inhibits macrophage lipid uptake in vitro. Arterioscler Thromb Vasc Biol (2009) 29:2021-7. doi:10.1161/ATVBAHA.109.195040.
56. Ketelhuth DF, Bäck M. The role of matrix metalloproteinases in atherothrombosis. Curr Atheroscler Rep (2011) 13:162-9. doi:10.1007/s11883-010-0159-7.
57. Kim SH, Lee WH, Kwon BS, Oh GT, Choi YH, Park JE. Tumor necrosis factor receptor superfamily 12 may destabilize atherosclerotic plaques by inducing matrix metalloproteinases. Circ J (2001) 65:136-8. doi:10.1253/jcj.65.136.
58. Mackman N. Role of tissue factor in hemostasis and thrombosis. Blood Cells Mol Dis (2006) 36:104-7. doi:10.1016/j.bmcd.2005.12.008.
59. Agirbasli M. Pivotal role of plasminogen-activator inhibitor 1 in vascular disease. Int J Clin Pract (2005) 59:102-6. doi:10.1111/j.1742-1241.2005.00379.x.
60. Muñoz-García B, Madrigal-Matute J, Moreno JA, Martin-Ventura JL, López-Franco O, Sastre C, et al. TWEAK-Fn14 interaction enhances plasminogen activator inhibitor 1 and tissue factor expression in atherosclerotic plaques and in cultured vascular smooth muscle cells. Cardiovasc Res (2011) 89:225-33. doi:10.1093/cvr/cvq278.
61. Lloyd-Jones D, Adams R, Carnethon M, De SG, Ferguson TB, Flegal K, et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2009) 119:480-6. doi:10.1161/CIRCULATIONAHA.108.191259.
62. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci (1999) 22:391-7. doi:10.1016/S0166-2236(99)01401-0.
63. Inta I, Frauenknecht K, Dörr H, Kohlhof P, Rabsilber T, Auffarth GU, et al. Induction of the cytokine TWEAK and its receptor Fn14 in ischemic stroke. J Neurol Sci (2008) 275:117-20. doi:10.1016/j.jns.2008.08.005.
64. Potrovita I, Zhang W, Burkly L, Hahm K, Lincecum J, Wang MZ, et al. Tumor necrosis factor-like weak inducer of apoptosis-induced neurodegeneration. J Neurosci (2004) 24:8237-44. doi:10.1523/JNEUROSCI.1089-04.2004.
65. Yepes M, Brown SA, Moore EG, Smith EP, Lawrence DA, Winkles JA. A soluble Fn14-Fc decoy receptor reduces infarct volume in a murine model of cerebral ischemia. Am J Pathol (2005) 166:511-20. doi:10.1016/S0002-9440(10)62273-0.
66. Zhang X, Winkles JA, Gongora MC, Polavarapu R, Michaelson JS, Hahm K, et al. TWEAK-Fn14 pathway inhibition protects the integrity of the neurovascular unit during cerebral ischemia. J Cereb Blood Flow Metab (2007) 27:534-44. doi:10.1038/sj.jcbfm.9600368.
67. Haile WB, Echeverry R, Wu F, Guzman J, An J, Wu J, et al. Tumor necrosis factor-like weak inducer of apoptosis and fibroblast growth factor-inducible 14 mediate cerebral ischemia-induced poly (ADP-ribose) polymerase-1 activation and neuronal death. Neuroscience (2010) 171:1256-64. doi:10.1016/j.neuroscience.2010.10.029.
68. del Zoppo GJ, Mabuchi T. Cerebral microvessel responses to focal ischemia. J Cereb Blood Flow Metab (2003) 23:879-94. doi:10.1097/01.WCB.0000078322.96027.78.
69. Rieckmann P, Engelhardt B. Building up the blood-brain barrier. Nat Med (2003) 9:828-9. doi:10.1038/nm0703-828.
70. Polavarapu R, Gongora MC, Winkles JA, Yepes M. Tumor necrosis factor-like weak inducer of apoptosis increases the permeability of the neurovascular unit through nuclear factor-kappa B pathway activation. J Neurosci (2005) 25:10094-100.
71. Blanco-Colio LM, Martín-Ventura JL, Muñóz-García B, Orbe J, Páramo JA, Michel JB, et al. Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler Thromb Vasc Biol (2007) 27:916-22. doi:10.1161/01.ATV.0000258972.10109.ff.
72. Kralisch S, Ziegelmeier M, Bachmann A, Seeger J, Lössner U, Blüher M, et al. Serum levels of the atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and end-stage renal disease. Atherosclerosis (2008) 199:440-4. doi:10.1016/j.atherosclerosis.2007.10.022.
73. Carrero JJ, Ortiz A, Qureshi AR, Martín-Ventura JL, Heimbürger O, Marrón B, et al. Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. Clin J Am Soc Nephrol (2009) 4:110-8. doi:10.2215/CJN.02790608.
74. Yilmaz MI, Carrero JJ, Ortiz A, Martín-Ventura JL, Sonmez A, Saglam M, et al. Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease. Clin J Am Soc Nephrol (2009) 4:1716-23. doi:10.2215/CJN.02760409.
75. Yilmaz MI, Carrero JJ, Martín-Ventura JL, Sonmez A, Saglam M, Celik T, et al. Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation. Clin J Am Soc Nephrol (2010) 5:1174-81. doi:10.2215/CJN.01110210.
76. Yilmaz MI, Sonmez A, Ortiz A, Saglam M, Kilic S, Eyileten T, et al. Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes. Clin J Am Soc Nephrol (2011) 6:785-92. doi:10.2215/CJN.09231010.
77. Jelic-Ivanovic Z, Bujisic N, Spasic S, Bogavac-Stanojevic N, Spasojevic-Kalimanovska V, Kotur-Stevuljevic J. Circulating sTWEAK improves the prediction of coronary artery disease. Clin Biochem (2009) 42:1381-6. doi:10.1016/j.clinbiochem.2009.06.001.
78. Chorianopoulos E, Rosenberg M, Zugck C, Wolf J, Katus HA, Frey N. Decreased soluble TWEAK levels predict an adverse prognosis in patients with chronic stable heart failure. Eur J Heart Fail (2009) 11:1050-6. doi:10.1093/eurjhf/hfp139.
79. Widlansky ME, Gokce N, Keaney JF Jr, Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol (2003) 42:1149-60. doi:10.1016/S0735-1097(03)00994-X.
80. Vita JA, Keaney JF Jr. Endothelial function: a barometer for cardiovascular risk? Circulation (2002) 106:640-2. doi:10.1161/01.CIR.0000028581.07992.56.
81. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam study. Circulation (1997) 128:262-9. doi:10.1161/01.CIR.96.5.1432.
82. Hassan SB, El-demery AB, Ahmed AI, Abukhalil RE. Soluble TWEAK and cardiovascular morbidity and mortality in chronic kidney disease patients. Arab J Nephrol Transplant (2012) 5:27-32.
83. Valdivielso JM, Coll B, Martín-Ventura JL, Moreno JA, Egido J, Fernández E, et al. Soluble TWEAK is associated with atherosclerotic burden in patients with chronic kidney disease. J Nephrol (2013) 26:1105-13. doi:10.5301/jn.5000245.
84. Turkmen K, Tonbul HZ, Erdur FM, Toker A, Biyik Z, Ozbiner H, et al. Soluble TWEAK independently predicts atherosclerosis in renal transplant patients. BMC Nephrol (2013) 14:144. doi:10.1186/1471-2369-14-144.
85. Gungor O, Kismali E, Sisman AR, Kircelli F, Carrero JJ, Tatar E, et al. The relationships between serum sTWEAK, FGF-23 levels, and carotid atherosclerosis in renal transplant patients. Ren Fail (2013) 35:77-81. doi:10.3109/0886022X.2012.734890.
86. Urbonaviciene G, Martin-Ventura JL, Lindholt JS, Urbonavicius S, Moreno JA, Egido J, et al. Impact of soluble TWEAK and CD163/TWEAK ratio on long-term cardiovascular mortality in patients with peripheral arterial disease. Atherosclerosis (2011) 219:892-9. doi:10.1016/j.atherosclerosis.2011.09.016.
87. McMahon M, Skaggs BJ, Grossman J, Sahakian L, Fitzgerald J, Wong WK, et al. A panel of biomarkers is associated with increased risk for the presence and progression of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum (2013) 66(1):130-9. doi:10.1002/art.38204.
88. Richter B, Rychli K, Hohensinner PJ, Berger R, Mörtl D, Neuhold S, et al. Differences in the predictive value of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in advanced ischemic and non-ischemic heart failure. Atherosclerosis (2010) 213:545-8. doi:10.1016/j.atherosclerosis.2010.08.061.
89. Coope HJ, Atkinson PG, Huhse B, Belich M, Janzen J, Holman MJ, et al. CD40 regulates the processing of NF-[kappa]B2 p100 to p52. EMBO J (2000) 21:5375-85. doi:10.1093/emboj/cdf542.
90. Claudio E, Brown K, Park S, Wang H, Siebenlist U. BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat Immunol (2002) 3:958-65. doi:10.1038/ni842.
91. Dejardin E, Droin NM, Delhase M, Haas E, Cao Y, Makris C, et al. The lymphotoxin-b receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity (2002) 17:525-35. doi:10.1016/S1074-7613(02)00423-5.
92. Novack DV, Yin L, Hagen-Stapleton A, Schreiber RD, Goeddel DV, Ross FP, et al. The IkappaB function of NF-kappaB2 p100 controls stimulated osteoclastogenesis. J Exp Med (2003) 198:771-81. doi:10.1084/jem.20030116.
93. Ramakrishnan P, Wang W, Wallach D. Receptor-specific signaling for both the alternative and the canonical NF-kappaB activation pathways by NF-kappaB-inducing kinase. Immunity (2004) 21:477-89. doi:10.1016/j.immuni.2004.08.009.
94. Lutgens E, Lievens D, Beckers L, Wijnands E, Soehnlein O, Zernecke A, et al. Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. J Exp Med (2010) 207:391-404. doi:10.1084/jem.20091293.
95. Zirlik A, Maier C, Gerdes N, MacFarlane L, Soosairajah J, Bavendiek U, et al. CD40 ligand mediates inflammation independently of CD40 by interaction with Mac-1. Circulation (2007) 115:1571-80. doi:10.1161/CIRCULATIONAHA.106.683201.
96. Lutgens E, Gorelik L, Daemen MJ, de Muinck ED, Grewal IS, Koteliansky VE, et al. Requirement for CD154 in the progression of atherosclerosis. Nat Med (1999) 5:1313-6. doi:10.1038/15271.
97. Lutgens E, Cleutjens KB, Heeneman S, Koteliansky VE, Burkly LC, Daemen MJ. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc Natl Acad Sci U S A (2000) 97:7464-9. doi:10.1073/pnas.97.13.7464.
98. Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature (1998) 394:200-3. doi:10.1038/28204.
99. Schonbeck U, Sukhova GK, Shimizu K, Match F, Libby P. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci U S A (2000) 97:7458-63. doi:10.1073/pnas.97.13.7458.
100. Bavendiek U, Zirlik A, LaClair S, MacFarlane L, Libby P, Schönbeck U. Atherogenesis in mice does not require CD40 ligand from bone marrow-derived cells. Arterioscler Thromb Vasc Biol (2005) 25:1244-9. doi:10.1161/01.ATV.0000161420.55482.ef.
101. Smook ML, Heeringa P, Damoiseaux JG, Daemen MJ, de Winther MP, Gijbels MJ, et al. Leukocyte CD40L deficiency affects the CD25(+) CD4 T cell population but does not affect atherosclerosis. Atherosclerosis (2005) 183:275-82. doi:10.1016/j.atherosclerosis.2005.03.051.
102. Lievens D, Zernecke A, Seijkens T, Soehnlein O, Beckers L, Munnix IC, et al. Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood (2010) 116:4317-27. doi:10.1182/blood-2010-01-261206.
103. Kyaw T, Tay C, Hosseini H, Kanellakis P, Gadowski T, MacKay F, et al. Depletion of B2 but not B1a B cells in BAFF receptor-deficient ApoE mice attenuates atherosclerosis by potently ameliorating arterial inflammation. PLoS One (2012) 7:e29371. doi:10.1371/journal.pone.0029371.
104. Sage AP, Tsiantoulas D, Baker L, Harrison J, Masters L, Murphy D, et al. BAFF receptor deficiency reduces the development of atherosclerosis in mice-brief report. Arterioscler Thromb Vasc Biol (2012) 32:1573-6. doi:10.1161/ATVBAHA.111.244731.
105. Kyaw T, Cui P, Tay C, Kanellakis P, Hosseini H, Liu E, et al. BAFF receptor mAb treatment ameliorates development and progression of atherosclerosis in hyperlipidemic ApoE(-/-) mice. PLoS One (2013) 8:e60430. doi:10.1371/journal.pone.0060430.
106. Gräbner R, Lötzer K, Döpping S, Hildner M, Radke D, Beer M, et al. Lymphotoxin β receptor signaling promotes tertiary lymphoid organogenesis in the aorta adventitia of aged ApoE -/- mice. J Exp Med (2009) 206:233-48. doi:10.1084/jem.20080752.
107. Bennett BJ, Scatena M, Kirk EA, Rattazzi M, Varon RM, Averill M, et al. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/-mice. Arterioscler Thromb Vasc Biol (2006) 26:2117-24. doi:10.1161/01.ATV.0000236428.91125.e6.
108. Morony S, Tintut Y, Zhang Z, Cattley RC, Van G, Dwyer D, et al. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in LDLR(-/-) mice. Circulation (2008) 117:411-20. doi:10.1161/CIRCULATIONAHA.107.707380.
109. van Olffen RW, de Bruin AM, Vos M, Staniszewska AD, Hamann J, van Lier RA, et al. CD70-driven chronic immune activation is protective against atherosclerosis. J Innate Immun (2010) 2:344-52. doi:10.1159/000314772.
110. Mach F, Schonbeck U, Sukhova GK, Bourcier T, Bonnefoy JY, Pober JS, et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA (1997) 94:1931-6.
111. Schonbeck U, Libby P. CD40 signaling and plaque instability. Circ Res (2001) 89:1092-103. doi:10.1161/hh2401.101272.
112. Lievens D, Eijgelaar WJ, Biessen EA, Daemen MJ, Lutgens E. The multi-functionality of CD40L and its receptor CD40 in atherosclerosis. Thromb Haemost (2009) 102:206-14. doi:10.1160/TH09-01-0029.
113. Ait-Oufella H, Herbin O, Bouaziz JD, Binder CJ, Uyttenhove C, Laurans L, et al. B cell depletion reduces the development of atherosclerosis in mice. J Exp Med (2010) 207:1579-87. doi:10.1084/jem.20100155.
114. Kyaw T, Tay C, Khan A, Dumouchel V, Cao A, To K, et al. Conventional B2 B cell depletion ameliorates whereas its adoptive transfer aggravates atherosclerosis. J Immunol (2010) 185:4410-9. doi:10.4049/jimmunol.1000033.
115. Kyaw T, Tay C, Krishnamurthi S, Kanellakis P, Agrotis A, Tipping P, et al. B1a B lymphocytes are atheroprotective by secreting natural IgM that increases IgM deposits and reduces necrotic cores in atherosclerotic lesions. Circ Res (2011) 109:830-40. doi:10.1161/CIRCRESAHA.111.248542.
116. Mackay F, Figgett WA, Saulep D, Lepage M, Hibbs ML. B-cell stage and context-dependent requirements for survival signals from BAFF and the B-cell receptor. Immunol Rev (2010) 237:205-25. doi:10.1111/j.1600-065X.2010.00944.x.
117. Miller DJ, Hayes CE. Phenotypic and genetic characterization of a unique B lymphocyte deficiency in strain A/WySnJ mice. Eur J Immunol (1991) 21:1123-30. doi:10.1002/eji.1830210506.
118. Houtkamp MA, de Boer OJ, van der Loos CM, van der Wal AC, Becker AE. Adventitial infiltrates associated with advanced atherosclerotic plaques: structural organization suggests generation of local humoral immune responses. J Pathol (2001) 193:263-9. doi:10.1002/1096-9896(2000)9999:9999<::AID-PATH774>3.0.CO;2-N.
119. Nolte MA, Belien JA, Schadee-Eestermans I, Jansen W, Unger WW, van Rooijen N, et al. A conduit system distributes chemokines and small blood-borne molecules through the splenic white pulp. J Exp Med (2003) 198:505-12. doi:10.1084/jem.20021801.
120. Tintut Y, Demer L. Role of osteoprotegerin and its ligands and competing receptors in atherosclerotic calcification. J Investig Med (2006) 54:395-401. doi:10.2310/6650.2006.06019.
121. Mosheimer BA, Kaneider NC, Feistritzer C, Sturn DH, Wiedermann CJ. Expression and function of RANK in human monocyte chemotaxis. Arthritis Rheum (2004) 50:2309-16. doi:10.1002/art.20352.
122. Sandberg WJ, Yndestad A, Øie E, Smith C, Ueland T, Ovchinnikova O, et al. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol (2006) 26:857-63. doi:10.1161/01.ATV.0000204334.48195.6A.
123. Kim J, Min JK, Park JA, Doh HJ, Choi YS, Rho J, et al. Receptor activator of nuclear factor kappaB ligand is a novel inducer of tissue factor in macrophages. Circ Res (2010) 107:871-6. doi:10.1161/CIRCRESAHA.110.221168.
124. Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol (2005) 23:23-68. doi:10.1146/annurev.immunol.23.021704.115839.
125. Chorianopoulos E, Jarr K, Steen H, Giannitsis E, Frey N, Katus HA. Soluble TWEAK is markedly upregulated in patients with ST-elevation myocardial infarction and related to an adverse short-term outcome. Atherosclerosis (2010) 211:322-6. doi:10.1016/j.atherosclerosis.2010.02.016.
126. Blanco-Colio LM, Martín-Ventura JL, Carrero JJ, Yilmaz MI, Moreno JA, Gómez-Guerrero C, et al. Vascular proteomics and the discovery process of clinical biomarkers: the case of TWEAK. Proteomics Clin Appl (2011) 5:281-8. doi:10.1002/prca.201000102.
127. Karadurmus N, Tapan S, Cakar M, Naharci I, Celik T, Tasci I, et al. Lower plasma soluble TWEAK concentration in patients with newly diagnosed hypertension. Clin Invest Med (2012) 35:E20-6.